LYRA, US55234L2043

Lyra Therapeutics stock centers on its nasal drug pipeline

Published on 10/16/2026 at 00:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lyra Therapeutics stock last traded OTC at USD 0.19 on October 13, 2026. Its nasal inserts target four million US patients.

Company facts and market context

Lyra Therapeutics listed April 17, 2026 as the date for its Nasdaq delisting intention.
Its two nasal insert candidates are designed for six months of drug delivery.
Lyra Therapeutics stock was last at USD 0.19 on October 13, 2026.

LYRA, US55234L2043, Illustration mit AI erstellt.

Lyra Therapeutics (ISIN US55234L2043) is developing two nasal insert candidates designed to deliver 7,500 mcg of mometasone furoate for six months, according to the Lyra Therapeutics investor-relations page. The stock was last at USD 0.19 in OTC trading on October 13, 2026.

Four million patients define the market

The company says its candidates target chronic rhinosinusitis, an inflammatory disease affecting an estimated four million US patients who fail medical management each year. The delivery design is intended to use a single in-office administration rather than repeated daily treatment, giving the clinical program a clear product distinction.

What does the platform deliver?

Lyra's two candidates, LYR-210 and LYR-220, are described as bioabsorbable nasal inserts for six months of continuous therapy. The investor-relations page identifies both programs as late-stage development projects and places the company's work in chronic rhinosinusitis.

Three corporate dates shape the record

On November 12, 2025, Lyra listed third-quarter results and a corporate update. On January 12, 2026, it listed a further corporate update. On April 17, 2026, it listed its intention to voluntarily file Form 25 for Nasdaq delisting and subsequent deregistration with the SEC, according to Lyra Therapeutics.

Stock context after the Nasdaq exit

The OTC quotation places the market focus on the company's remaining development assets rather than on an active Nasdaq listing. The latest quoted price of USD 0.19 gives investors a dated reference point, while the product profile supplies the operating context behind the security.

Upcoming dates

The investor-relations page lists no future reporting date in the displayed events section. Its latest listed event is the June 2, 2025 ENLIGHTEN 2 Phase 3 results presentation.

Price stays at a dated OTC level

Lyra Therapeutics was last at USD 0.19 in OTC trading on October 13, 2026. The company profile centers on two nasal insert candidates designed for six months of therapy.